Globally, breast cancer remains the most common cancer among women and the leading cause of cancer death among women globally. The World Health Organization (WHO) underlines that not only are around 8.2 million women living with a history of breast cancer globally, but approximately 2.4 million new breast cancer cases are diagnosed each year globally, per the American Cancer Society’s report.
Getting a breast cancer diagnosis is always a shock, but imagine your healthcare provider telling you that they’ve “got it all” after removing the tumor! There’s usually relief, until the next hard questions roll in. And that’s a big one: will I need chemotherapy, even when the cancer is gone? Chemotherapy might be life-saving, but it’s not fun. Most people picture months of harsh treatment, losing hair, feeling tired and sick, and watching their immune system take a hit. The truth is, not every breast cancer patient actually benefits from chemo. For some, it’s essential. For others, it doesn’t make a big difference in their survival odds.
Now, a major international study is shining a light on who really needs chemotherapy and who might be able to skip it safely. Researchers at University College London (UCL) uncovered some encouraging evidence using a gene-expression test called Prosigna. Their data suggest this test can flag certain early-stage breast cancer patients who can avoid chemo, with no loss in long-term safety or outcomes. The findings, announced in October 2026, brought two major hopes front and centre: more tailored cancer care and thousands of patients spared from unnecessary treatment. And let’s face it, there’s also a bonus for healthcare budgets.
However, it’s important to note that we’re not talking about getting rid of chemotherapy for breast cancer — not by a long shot. And no one should decide their treatment based on a gene test alone. What’s really changing is how cancer doctors pick treatments, focusing less on a “one-size-fits-all” formula and more on what’s actually driving the tumor in each person.
Here’s a closer look at what this new research actually found, how the gene test works, who it’s really for, and what it means for breast cancer treatment plans in the real world.